Join Growin Stock Community!

Inhibrx biosciences, inc.INBX.US Overview

US StockHealthcare
(No presentation for INBX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

INBX AI Insights

INBX Overall Performance

INBX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INBX Recent Performance

-5.46%

Inhibrx biosciences, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

INBX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

INBX Key Information

INBX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

INBX Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Price of INBX

INBX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

INBX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.66
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
770.09
PB Ratio
29.27
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-11077.57%
Revenue Growth (YoY)
-19.26%
Profit Growth (YoY)
-2.51%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
46.76%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.66
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
770.09
PB Ratio
29.27
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-11077.57%
Revenue Growth (YoY)
-19.26%
Profit Growth (YoY)
-2.51%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
46.76%

  • When is INBX's latest earnings report released?

    The most recent financial report for Inhibrx biosciences, inc. (INBX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INBX's short-term business performance and financial health. For the latest updates on INBX's earnings releases, visit this page regularly.

  • How much debt does INBX have?

    As of the end of the reporting period, Inhibrx biosciences, inc. (INBX) had total debt of 106.91M, with a debt ratio of 0.6. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does INBX have?

    At the end of the period, Inhibrx biosciences, inc. (INBX) held Total Cash and Cash Equivalents of 153.09M, accounting for 0.86 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is INBX's EPS continuing to grow?

    According to the past four quarterly reports, Inhibrx biosciences, inc. (INBX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INBX?

    Inhibrx biosciences, inc. (INBX)'s Free Cash Flow (FCF) for the period is -33.83M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 10.82% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of INBX?

    The latest valuation data shows Inhibrx biosciences, inc. (INBX) has a Price-To-Earnings (PE) ratio of -7.42 and a Price/Earnings-To-Growth (PEG) ratio of -0.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.